Founded in 2021, Laibo Ruichen is committed to the independent research and development and industrialization promotion of "First-in-Class" innovative drugs for bone and joint, and provides innovative treatment programs for the majority of bone and joint patients based on the unmet clinical drug demand in China and the world.

The original project team is from UC Davis Bone and Joint Regenerative Medicine Research Center; R&D has been carried out for more than 12 years, and the accumulated investment exceeds 30 million US dollars; Global originality, leading technology and high barriers can fill the gap in the market; The intellectual property rights are clear and authorized, and the research and development achievements have been published in many top scientific magazines in the world.

To build an internationally advanced bone & joint medicine company in China, which is competent for drug design, synthesis, preclinical and clinical research, development and commercialization of innovative drugs for bone and joint diseases.

Since establishment, Rabpharma has reached several key milestones --- completing Phase II patient enrollment for RAB001 and securing 3 funding rounds.​​Honors and qualifications include:​​ Provincial Specialized, Refined, Unique and Innovative SME, Postdoctoral Workstation, the "Outstanding Enterprise Award" from the China Innovation & Entrepreneurship Competition, and the "Mercury" Enterprise honor from the National Disruptive Tech Star Awards, etc.